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ORIGINAL INVESTIGATION
Diabetes status-related differences 
in risk factors and mediators of heart 
failure in the general population: results 
from the MORGAM/BiomarCaRE consortium
Matti A. Vuori1,2* , Jaakko Reinikainen2, Stefan Söderberg3, Ellinor Bergdahl3, Pekka Jousilahti2, 
Hugh Tunstall‑Pedoe4, Tanja Zeller5, Dirk Westermann5, Susana Sans6, Allan Linneberg7,8, Licia Iacoviello9,10, 
Simona Costanzo8, Veikko Salomaa2, Stefan Blankenberg5, Kari Kuulasmaa2 and Teemu J. Niiranen1,2 
Abstract 
Background: The risk of heart failure among diabetic individuals is high, even under tight glycemic control. The 
correlates and mediators of heart failure risk in individuals with diabetes need more elucidation in large population‑
based cohorts with long follow‑up times and a wide panel of biologically relevant biomarkers.
Methods: In a population‑based sample of 3834 diabetic and 90,177 non‑diabetic individuals, proportional hazards 
models and mediation analysis were used to assess the relation of conventional heart failure risk factors and biomark‑
ers with incident heart failure.
Results: Over a median follow‑up of 13.8 years, a total of 652 (17.0%) and 5524 (6.1%) cases of incident heart failure 
were observed in participants with and without diabetes, respectively. 51.4% were women and the mean age at 
baseline was 48.7 (standard deviation [SD] 12.5) years. The multivariable‑adjusted hazard ratio (HR) for heart failure 
among diabetic individuals was 2.70 (95% confidence interval, 2.49–2.93) compared to non‑diabetic participants. In 
the multivariable‑adjusted Cox models, conventional cardiovascular disease risk factors, such as smoking (diabetes: 
HR 2.07 [1.59–2.69]; non‑diabetes: HR 1.85 [1.68–2.02]), BMI (diabetes: HR 1.30 [1.18–1.42]; non‑diabetes: HR 1.40 
[1.35–1.47]), baseline myocardial infarction (diabetes: HR 2.06 [1.55–2.75]; non‑diabetes: HR 2.86 [2.50–3.28]), and 
baseline atrial fibrillation (diabetes: HR 1.51 [0.82–2.80]; non‑diabetes: HR 2.97 [2.21–4.00]) had the strongest associa‑
tions with incident heart failure. In addition, biomarkers for cardiac strain (represented by nT‑proBNP, diabetes: HR 1.26 
[1.19–1.34]; non‑diabetes: HR 1.43 [1.39–1.47]), myocardial injury (hs‑TnI, diabetes: HR 1.10 [1.04–1.16]; non‑diabetes: 
HR 1.13 [1.10–1.16]), and inflammation (hs‑CRP, diabetes: HR 1.13 [1.03–1.24]; non‑diabetes: HR 1.29 [1.25–1.34]) were 
also associated with incident heart failure. In general, all these associations were equally strong in non‑diabetic and 
diabetic individuals. However, the strongest mediators of heart failure in diabetes were the direct effect of diabetes 
status itself (relative effect share 43.1% [33.9–52.3] and indirect effects (effect share 56.9% [47.7‑66.1]) mediated by 
obesity (BMI, 13.2% [10.3–16.2]), cardiac strain/volume overload (nT‑proBNP, 8.4% [‑0.7–17.4]), and hyperglycemia 
(glucose, 12.0% [4.2–19.9]).
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other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line 
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory 
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this 
licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/. The Creative Commons Public Domain Dedication waiver (http:// creat iveco 
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Background
Diabetes mellitus is an established heart failure (HF) risk 
factor. Already in 1974, the Framingham Heart Study 
investigators observed five- and two-fold increases in 
HF risk in diabetic women and men compared to their 
non-diabetic counterparts [1]. In addition, a recent sys-
tematic review by Aune et al. that covered over 21 million 
participants reported a doubled HF risk among diabetic 
patients [2]. In fact, 45% of patients hospitalized for HF 
have diabetes [3]. This association between diabetes 
and HF has been historically considered to be driven by 
increased coronary atherosclerosis in diabetic individu-
als. However, in contrast to this assumption, HF risk is 
also elevated among diabetic individuals without coro-
nary heart disease [4] and in diabetic patients under rig-
orous glycaemic control [5]. These findings suggest that 
factors apart from coronary atherosclerosis may contrib-
ute to the increased HF risk in diabetes.
Potential non-atherosclerotic cardiometabolic causes 
for the increased HF risk in diabetes include subclinical 
inflammation, obesity, alterations in the lipid and energy 
metabolism, endothelial dysfunction and a cardiac mus-
cle disease seen in diabetes, termed diabetic cardiomyo-
pathy, that is unrelated to hypertension, coronary artery 
disease, or dyslipidemia [6, 7]. Reduced kidney function 
and related physiologic alterations may also contribute to 
the HF risk in patients with diabetes through intravascu-
lar volume overload, altered reabsorption or excretion of 
filtered glucose and/or sodium [8]. In addition, vitamin D 
levels are often low in individuals with obesity or insulin 
resistance and are also related to a wide range of cardio-
vascular and metabolic disorders as well, but ascertaining 
links to certain disease states, such as HF, have been dif-
ficult to make due to the relatively high prevalence of low 
vitamin D levels [9, 10].
The potential underlying and mediating factors of HF 
in diabetes are numerous and remain understudied in 
large well-phenotyped population cohorts with long 
enough follow-up times needed for HF to develop. We 
hypothesize that using survival modeling and mediation 
analyses will help in clarifying the differences between 
diabetic and non-diabetic individuals in developing HF. 
This information could help us understand the patho-
physiology and the disproportionately increased risk of 
HF among individuals with diabetes. To reach this goal, 
both conventional HF risk factors and circulating bio-
markers were measured in a large multinational pool of 
population-based cohorts of 94,011 individuals (55,271 
with biomarkers available) with follow-up times up to 




The MORGAM (MOnica Risk, Genetics, Archiving 
and Monograph) project is a multinational collabora-
tive study with harmonized data from population-based 
cohort studies. The project aims at exploring the rela-
tionships between the development of cardiovascular 
diseases, their classic and genetic risk factors and bio-
markers, originating from the WHO MONICA [Mul-
tinational MONItoring of trends and determinants in 
CArdiovascular disease] projects [11, 12]. Follow-up 
data for incident hospitalization for HF and its risk fac-
tors for up to 29 years (median 14.1 years) are available 
for 115,868 individuals from 20 cohorts from 6 countries: 
the FINRISK Study from Finland (baseline data collec-
tion carried out every 5  years between 1982–2007 with 
biomarker assessment in 1997), the Northern Sweden 
MONICA Study (1986–2009), the DAN-MONICA from 
Denmark (1982–1992), the Moli-sani Study from Italy 
(2005–2010), and the Scottish Heart Health Extended 
Cohort [SHHEC] from the UK (1984–1995).
After pooling these cohorts together, we derived two 
study samples that were included in the final analyses. 
Study sample 1 had complete HF follow-up data available 
(n = 94,011 after exclusions) and study sample 2 had also 
biomarker data available, being a subsample of the first 
one (n = 55,271 after exclusions; details in Fig. 1).
Data collection
The diagnostic criteria for baseline disease states var-
ies by cohort and baseline year but is mainly based 
on  International Classification of Diseases (ICD) codes 
in hospital discharge data for all cohorts [13]. In general, 
baseline HF was defined with positive replies to survey 
questions (e.g., “Have you ever been diagnosed with…”, 
“Has a healthcare professional ever told you you have…”), 
Conclusions: The findings suggest that the main mediators of heart failure in diabetes are obesity, hyperglycemia, 
and cardiac strain/volume overload. Conventional cardiovascular risk factors are strongly related to incident heart 
failure, but these associations are not stronger in diabetic than in non‑diabetic individuals. Active measurement of rel‑
evant biomarkers could potentially be used to improve prevention and prediction of heart failure in high‑risk diabetic 
patients.
Keywords: Diabetes, Cardiovascular disease, Heart failure, Mediation, Hazard, Risk, Biomarker
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hospital discharge register diagnoses (available in FIN-
RISK, DAN-MONICA, SHHEC and Northern Sweden 
MONICA studies), or other health care information 
system (such as linkage with the nationwide Drug Reim-
bursement Register in FINRISK). Prevalent diabetes was 
based on self-report and/or register diagnoses (Addi-
tional file 1: Table S1a). Some early surveys did not dif-
ferentiate between type 1 and type 2 diabetes and for this 
reason they were analyzed jointly (however, 16% of the 
diabetic participants were receiving insulin treatment at 
baseline). Detailed information on data collection, data 
harmonization, and definition of prevalent and incident 
disease is available for each cohort online [12].
Biomarker data
Biomarkers used in this study were creatinine, C-reactive 
protein (hs-CRP), glucose, insulin, HDL cholesterol, LDL 
cholesterol, triglycerides, C-peptide, n-terminal atrial 
natriuretic peptide, type B (nT-proBNP), troponin I (hs-
TnI), and vitamin D. High sensitivity assays were used for 
CRP and TnI. All biomarkers were sampled at baseline, 
deep-frozen and subsequently analyzed in the same cen-
tral laboratory, except total cholesterol and HDL, which 
were mainly analyzed locally and during the same day 
as venous sampling (for Northern Sweden MONICA in 
1999–2008, HDL cholesterol was measured from frozen 
samples in the aforementioned central laboratory). All 
lipids were serum measurements with > 10  h of fasting 
in Moli-sani and DAN-MONICA, > 4 h in FINRISK and 
Northern Sweden MONICA projects, while no fasting 
was required in SHHEC, which can mainly affect triglyc-
erides levels. Low-density lipoprotein (LDL) cholesterol 
levels were calculated using the Friedewald formula 
without any additional hypertriglyceridemia-related 
adjustments. The laboratory methods and quality con-
trol results of the biomarkers have been published earlier 
[14].
Follow‑up
After excluding persons with HF at baseline from the 
study, the subjects were followed up for their first diagno-
sis of HF. The follow-up procedures relied on data from 
national population registers (except in Moli-sani), hos-
pital discharge registers, causes-of-death registers, and 
death certificates. The follow-up periods started between 
1982 and 2005 and ended between 2010 and 2015. Cen-
soring was performed if the subject died from other cause 
or was lost to follow-up. Cohort-specific diagnostic cri-
teria and follow-up period details with exact ICD codes 
used for HF and diabetes diagnosis at baseline and fol-
low-up are combined in the Additional file 1: Table S1b 
and also provided online [12].
Definitions
Smoking was defined as self-reported regular and occa-
sional use of any of the following products: cigarettes, 
cigarillos, pipes, or cigars. Blood pressure (BP) was meas-





































7,526 36,907 10,370 15,959 23,397
Fig. 1 Flow chart for pooling population cohorts and exclusions made to form the population samples to be studied. Sample 2 is a subsample of 
Sample 1. All steps have been made for all cohorts but numbers after exclusions are illustrated only when the corresponding n is smaller due to 
them. MONICA Multinational Monitoring of trends and determinants in Cardiovascular disease, SHHEC Scottish Heart Health Extended Cohort, HF 
heart failure
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automated device and the mean of both measurements 
was used. Height and weight were measured with stand-
ard methods to calculate body mass index (BMI). Aver-
age alcohol use was calculated as grams per day (g/d) 
based on self-report.
Statistical analyses
As the biomarker data were highly skewed to the right 
(i.e., a vast majority of cases were in the low or very low 
end of the range), we performed appropriate transforma-
tions (square root for lipid data and cubic root for the 
rest) and winsorizing (replacing the three highest val-
ues with the fourth highest) to avert further skewness 
caused by extreme outliers. After transformations, miss-
ing data were handled using multiple imputation with 
ten imputed data sets. We used random forests as the 
imputation method and ensured the convergence of the 
imputation algorithm and plausibility of imputed values 
by graphical inspection. After this, the continuous varia-
bles were centered by subtracting the variable mean from 
each variable and scaled by dividing the centered variable 
values by their standard deviations.
The unadjusted association between diabetes status 
and incident HF was assessed by estimating cumula-
tive incidence curves for HF in the whole study sample 
1 while the association between different risk factors and 
HF was examined using Cox proportional hazards mod-
els in study sample 2. The risk factors consisted of con-
ventional HF risk factors (sex, alcohol use, systolic BP, 
BMI, smoking, baseline myocardial infarction [MI], and 
baseline atrial fibrillation [AF]) and several biomarkers 
(HDL cholesterol, LDL cholesterol, triglycerides, glucose, 
insulin, nT-proBNP, hs-TnI, creatinine, hs-CRP, and vita-
min D). The analyses were performed separately for dia-
betic and non-diabetic individuals. We fitted models with 
different levels of adjustment to assess the impact of con-
trolling for other variables. First, all risk factors were ana-
lyzed in separate models adjusted for conventional HF 
risk factors and stratified by cohort. Then, all risk factors 
were included as predictor variables in the same model 
and stratified by cohort. In addition, to test whether the 
association between the risk factor and HF was statisti-
cally different in diabetic versus non-diabetic individuals, 
an interaction term between a risk factor and diabetes 
status was included, in separate models for each risk fac-
tor. It is recommended to use age as time-scale instead 
of parametric adjustment as a covariate as parametric 
adjustment assumes that the connection between age 
and disease is known. In contrast, age as time-scale does 
not assume this and results in better visualization of the 
connection [15–17]. For this reason, age was used as the 
time-scale in all Cox models, resulting in age-adjustment.
An exploratory mediation analysis with selected risk 
factors as potential mediator variables between diabe-
tes and incident HF was performed in study sample 2. 
The conceptual model of the mediation analysis and 
the direct and indirect mediation effects are illustrated 
in Fig.  2. Baseline diabetes status (established before 
the baseline measurements) was used as the exposure 
variable and incident HF (during follow-up time) as the 
outcome variable, with the baseline biomarkers or con-
ventional risk factors included as potential mediators 
Fig. 2 Conceptual model for mediation analysis. The effect of diabetes mellitus on the incidence of heart failure is divided to direct effect and 
mediator‑driven effect. Covariates associated with the incidence of HF are depicted on the right. An individual’s age is taken into account by using 
age as the time‑scale in the HF‑free survival model. HF heart failure, BP blood pressure, MI myocardial infarction, AF atrial fibrillation, CRP C‑reactive 
protein, nT-proBNP n‑terminal atrial natriuretic peptide, type B, hs high‑sensitivity assay, TnI troponin I
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of diabetes status on the outcome. We chose to exclude 
behavioral variables (smoking status and alcohol intake) 
from the mediation analysis as the effect of diabetes on 
HF onset cannot be expressed through them. To select 
the variables to be treated as potential mediators, we 
followed the approach presented by Yu et al. [18]. For a 
variable to be considered as a potential mediator, i.e., to 
be able to convey the predictor’s effect in the outcome, it 
needed to be significantly associated with both diabetes 
(exposure) and HF (outcome, with significance level of 
p < 0.1), when other variables were controlled for. When 
the aforementioned tests were not passed for a variable, 
it was used as a covariate by default. After applying these 
rules, systolic BP, BMI, HDL cholesterol, glucose, tri-
glycerides, creatinine, CRP, nT-proBNP, hs-TnI, baseline 
MI, baseline AF, and vitamin D were included as media-
tor variables whereas sex and cohort were included as 
covariates.
All analyses were performed using R statistical soft-
ware, version 3.5.1 [19]. The mediation analysis was 
performed using the mma-package [20] and multiple 
imputation using the mice-package [21].
Results
The characteristics of the two study samples are pre-
sented in Table  1. In the full study sample (n = 94,011), 
51.4% were women and mean age at baseline was 48.7 
(standard deviation [SD] 12.5) years. Of this sample, 
3834 (4.1%) individuals had baseline diabetes. Of per-
sons with diabetes, 15.8% had insulin treatment, 37% 
had oral hypoglycemic medication, and 25.8% received 
only dietary treatment, suggesting that at least over 70% 
of these participants had type 2 diabetes. Incident HF 
was more common among diabetic individuals (n = 652; 
17.0%) than among non-diabetic individuals (n = 5524; 
6.1%) over a median follow-up time of 13.8 (interquar-
tile range 5.7−22.8) years. Unadjusted cumulative HF 
incidence curves for diabetic and non-diabetic individu-
als in the study sample 1 over a follow-up time of up to 
29.0 years are presented in Fig. 3. The hazard ratio (HR) 
for HF among diabetic individuals was 2.70 (95% confi-
dence interval [CI], 2.49 − 2.93) when compared to non-
diabetic participants. 
The associations of each risk factor with incident HF 
among diabetic and non-diabetic individuals are pre-
sented in Fig.  4 (separate models for each risk factor) 
and Fig. 5 (all risk factors included in the same model). 
In both analyses, we observed that conventional risk 
factors (male sex, BMI, smoking, prevalent MI, and 
prevalent AF) were more strongly related to HF in both 
diabetic and non-diabetic individuals than the circulat-
ing biomarkers, except for nT-proBNP which was asso-
ciated with HF in both groups (HR 1.26 [CI 1.19 − 1.34] 
for diabetic and 1.43 [1.39 − 1.47] for non-diabetic 
individuals).
When the risk factors were analysed in separate mod-
els (Fig. 4), male sex, BMI, smoking, baseline MI, triglyc-
erides, glucose, nT-proBNP, hs-TnI and hs-CRP were 
directly related to increased HF risk in both diabetic and 
non-diabetic individuals. HDL cholesterol and vitamin 
D were inversely related to the increased risk in both 
groups. Systolic BP, baseline AF and creatinine reached 
a statistically significant association with increased HF 
risk in non-diabetic individuals only whereas insulin lev-
els were significantly associated with HF in diabetic indi-
viduals only. Interactions terms between diabetes status 
and systolic BP, baseline MI, baseline AF, nT-proBNP, and 
hs-CRP as HF risk factors were statistically significant 
and these associations tended to be stronger in the non-
diabetic individuals. The p-value for the interaction term 
between glucose and diabetes status was 0.067 and thus 
trended towards significance. Alcohol use and LDL cho-
lesterol were not related to HF risk in either diabetic or 
non-diabetic individuals in this study.
In the joint analysis with all risk factors included in the 
same model (Fig.  5), BMI, smoking, baseline history of 
MI, low HDL cholesterol, triglycerides, nt-proBNP, and 
low vitamin D were associated with increased HF risk in 
both diabetic and non-diabetic individuals. Systolic BP, 
baseline AF, hs-TnI, and hs-CRP were significantly linked 
to increased risk of HF in only non-diabetic individuals 
whereas glucose levels were significantly associated only 
in diabetic individuals. We observed a significant interac-
tion between diabetes status and systolic BP for HF risk 
suggesting a stronger association in diabetic than in non-
diabetic individuals. Alcohol use, LDL-cholesterol, insu-
lin, and creatinine were not related to HF risk in either 
diabetic or non-diabetic individuals. A correlation matrix 
for all risk factors used in these analyses is reported in 
Additional file  1: Table  S3. In sex-specific analyses, low 
alcohol intake was related to low risk of HF in women 
with diabetes (women: HR 0.64 [95 CI, 0.43–0.96]; men: 
HR 0.96 [95 CI, 0.80–1.14]). Heavy smoking was related 
to HF in both men and women with diabetes, but this 
association was particularly strong in women with dia-
betes (women: HR 3.96 [95 CI, 2.56–6.14]; men: HR 1.68 
[95 CI, 1.21–2.34]). For biomarkers, the associations with 
HF were mainly similar in men and women, with the 
exception of nT-proBNP (women: HR 1.19 [95 CI, 1.08–
1.31]; men: HR 1.31 [95 CI, 1.20–1.42]).
To further elucidate the effect of risk factors and the 
role of diabetes on HF incidence, we performed a media-
tion analysis with selected risk factors included as medi-
ators of diabetes on the onset of HF in the sample with 
biomarker data (Fig.  6). The effect of diabetes status on 
HF risk was only partially explained by the mediators’ 
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Table 1 Characteristics of the study samples
Data presented as n (% of either overall, diabetic, or non-diabetic population) for categorical and as mean (standard deviation) for continuous variables regarding 
demographics, diabetes treatment and risk factors, and as median (Q1-Q3) before transformations (square root for HDL, LDL and triglycerides, cube root for others), 
winsorizing and imputations for biomarkers. Missing data information is presented as n (% of overall) missing for demographics, risk factors and biomarkers, n (% of 
individuals with diabetes) for diabetes treatment, and for biomarkers also as number imputed. Values for continuous variables are from regular ANOVA with equal 
variance assumption and for categorical variables from chi-squared tests with continuity correction. p values for all values < 0.001 except for Alcohol use (p = 0.45 in 
Sample 1 and = 0.484 in Sample 2)
NA not available, MONICA Multinational Monitoring of trends and determinants in Cardiovascular disease, SHHEC Scottish Heart Health Extended Cohort, MI 
myocardial infarction, AF atrial fibrillation, CHD coronary heart disease, BP blood pressure, HF heart failure, CRP C-reactive protein; nT-proBNP n-terminal atrial 
natriuretic peptide, type B, hs high sensitivity assay, TnI troponin I, HDL HDL cholesterol, LDL LDL cholesterol
Sample 1 (whole sample: DAN‑MONICA, FINRISK, Moli‑
sani, SHHEC, Northern Sweden MONICA)
Sample 2 (sample with biomarker data available: FINRISK, Moli‑sani, 
SHHEC, Northern Sweden MONICA)
Overall Diabetes No diabetes Missing, n (%) Overall Diabetes No diabetes Missing, n (%)
Demographics
 n 94,011 (100) 3,834 (100) 90,177 (100) 55,271 (100) 2,472 (100) 52,799 (100)
Cohort
 DAN‑MONICA 7,526 (8.0) 178 (4.6) 7,348 (8.1)
 FINRISK 36,907 (39.3) 1,526 (39.8) 35,381 (39.2) 7,852 (14.2) 397 (16.1) 7,455 (14.1)
 Moli‑sani 23,249 (24.7) 1,468 (38.3) 21,781 (24.2) 23,198 (42.0) 1,465 (59.3) 21,733 (41.2)




10,370 (11.0) 386 (10.1) 9,984 (11.1) 10,031 (18.2) 371 (15.0) 9,660 (18.3)
Women 48,320 (51.4) 1,771 (46.2) 46,549 (51.6) 28,307 (51.2) 1,066 (43.1) 27,241 (51.6)




13,522 (14.4) 1,632 (42.6) 11,890 (13.1) 3,284 (3.5) 9,833 (17.8) 1,199 (48.5) 8,634 (16.4) 412 (0.7)
 Lipid lowering 
treatment
3,099 (3.3) 579 (15.1) 2,520 (2.8) 30,281 (32.2) 2,465 (4.5) 479 (19.4) 1,986 (3.8) 15,704 (28.4)
 Diabetes treatment
  Oral 1,427 (37.2) 810 (21.1) 1,148 (46.4) 518 (21.0)
  Insulin 607 (15.8) 810 (21.1) 388 (15.7) 518 (21.0)
  Diet 990 (25.8) 810 (21.1) 418 (16.9) 518 (21.0)
Risk factors
 Alcohol use, g/d 10.82 (18.0) 10.60 (18.7) 10.83 (18.0) 2,343 (2.5) 12.13 (19.4) 12.41 (20.0) 12.12 (19.4) 1,937 (3.5)
 BMI, kg/m2 26.17 (4.6) 29.16 (5.5) 26.05 (4.5) 806 (0.9) 26.61 (4.7) 29.56 (5.5) 26.47 (4.6) 97 (0.2)
 Smokers 29,914 (31.8) 862 (22.5) 29,052 (32.2) 161 (0.2) 16,140 (29.2) 475 (19.2) 15,665 (29.7) 42 (0.1)
 Systolic BP, 
mmHg
135.23 (20.6) 145.80 (22.0) 134.79 (20.4) 761 (0.8) 135.66 (20.8) 147.42 (22.0) 135.11 (20.6) 15 (0.0)
 Baseline MI 2,194 (2.3) 303 (7.9) 1,891 (2.1) 289 (0.3) 1,450 (2.6) 215 (8.7) 1,235 (2.3) 228 (0.4)
 Baseline AF 560 (0.6) 51 (1.3) 501 (0.6) 6,328 (6.8) 423 (0.8) 51 (2.1) 372 (0.7) 6,371 (11.5)
Biomarkers
 HDL, mmol/l 1.4 (1.2 − 1.7) 1.3 (1.1 − 1.5) 1.4 (1.2 − 1.7) 2996 (5.4)
 LDL, mmol/l 3.0 (2.4 − 3.8) 2.9 (2.3 − 3.5) 3.0 (2.4 − 3.8) 3019 (5.4)
 Triglycerides, 
mmol/l
1.2 (0.9 − 1.7) 1.4 (1.0 − 1.9) 1.20 (0.9 − 1.6) 2956 (5.3)
 Insulin, pmol/l 6.6 (4.5 − 10.0) 9.6 (6.2 − 15.4) 6.5 (4.4 − 9.8) 1894 (3.4)
 Glucose, mmol/l 4.9 (4.5 − 5.5) 7.3 (5.8 − 9.5) 4.9 (4.5 − 5.4) 3,466 (6.2)
 Creatinine, 
μmol/l
70.7 (61.9 − 79.6) 72.5 (63.6 − 85.7) 70.7 (61.9 − 79.6) 1120 (2.0)
 hs‑CRP, mg/l 1.4 (0.6 − 2.9) 2.0 (0.9 − 4.3) 1.3 (0.6 − 2.8) 1109 (2.0)
 nT‑proBNP, pg/ml 48.3 (25.5 − 90.2) 67.1 (32.5 − 143.3) 47.7 (25.3 − 88.1) 6678 (12.1)
 hs‑TnI, pg/ml 2.5 (1.4 − 4.3) 3.2 (2.0 − 5.5) 2.4 (1.4 − 4.2) 2643 (4.8)
 Vitamin D, ng/ml 16.2 (11.5 − 22.4) 15.3 (11.0 − 20.7) 16.2 (11.5 − 22.4) 2543 (4.6)
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effects (relative effect of all mediators was 56.9% [95% 
CI 47.7 − 66.1%)] of the whole effect) and a consider-
able direct effect of diabetes (relative effect 43.1%; 95% 
CI 33.9 − 52.3%) was observed. The strongest mediator 
effects were seen with those represented by BMI (rela-
tive effect 13.2%; 95% CI, 10.3 − 16.2%), glucose (12.0%, 
95% CI, 4.2 − 19.9%), and nT-proBNP (8.4%, 95% CI, 
-0.07–14.1%). Weak, but statistically significant media-
tion effects were also observed for the effects represented 
by systolic BP, HDL cholesterol, triglycerides, hs-TnI, hs-
CRP, vitamin D and baseline histories of MI and AF. The 
effects of insulin and creatinine were selected as covari-
ates by the algorithm (in addition to sex and stratified 
cohort, decided in advance).
Discussion
In this study, our goal was to elucidate the key corre-
lates and mediators of HF in diabetic individuals. This 
study confirms the strong association between diabetes 
and incident HF. Conventional cardiovascular disease 
risk factors, such as male sex, smoking, BMI, baseline 
MI, and baseline AF were the strongest correlates of 
incident HF in the Cox models. In addition, biomark-
ers for volume overload/cardiac strain (represented by 
nT-proBNP), myocardial injury (hs-TnI), and inflam-
mation (hs-CRP) were also associated with incident HF. 
In general, all these associations were equally strong in 
non-diabetic and in diabetic individuals. However, the 
strongest indirect mediators of diabetes on incident HF 
were the effects represented by BMI, hyperglycemia, and 
volume overload/cardiac strain (the effect represented 
by nT-proBNP), and with a considerable direct effect of 
prevalent diabetes status itself as the biggest single driver 
of HF.
We expected to observe the strongest associations 
between traditional cardiovascular disease risk factors 
(such as sex, smoking, BMI, and prior cardiovascular 
disease) and incident HF in the Cox models. However, 
these factors were not in general more strongly related to 
HF in diabetic than in non-diabetic individuals nor were 
their effects strong mediators of diabetes on HF risk, with 
the notable exception for the effect represented by BMI. 
However, even though this relative risk per unit is simi-
lar, diabetic patients are likely to have higher BMI and BP 
levels, which lead to higher absolute risk of HF. Also, the 
majority of diabetic patients in our study received anti-
hypertensive medication which may confound the asso-
ciation between BP and HF. Furthermore, smoking was 
one of the stronger risk factors for HF both in diabetic 
and non-diabetic individuals, especially in women. This 
observation is in accordance with a previous meta-anal-
ysis and it emphasizes the importance of smoking cessa-
tion in HF prevention [22]. The lack of association of HF 
with alcohol use is also in agreement with other studies 
[23]. Heavy drinkers, however, most likely do not take 
part in health studies adding a major confounding effect 
to studies researching associations of heavy drinking. 
These conventional cardiovascular disease risk factors do 
not, however, explain the greater than expected HF risk 
in diabetic patients [1].
The relation of hyperglycemia and HF among dia-
betic and non-diabetic populations has been assessed 
Fig. 3 Unadjusted cumulative HF incidence curves for diabetic and non‑diabetic individuals in the study sample 1. Total number of participants 
in analyses is 94,011. A total of 652 (17.0%) and 5524 (6.1%) cases of incident heart failure were observed in 3834 and 90,177 individuals with and 
without diabetes, respectively. Shaded area represents the 95% confidence interval and ticks the censored subjects. Log rank P value < 0.001. 
Numbers of events, censored events and individuals at risk at selected points are provided in Additional file 1: Table S2. HF heart failure, HR hazard 
ratio
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Fig. 4 Association between risk factors and incident heart failure in diabetic and non‑diabetic individuals with each risk factor analyzed in an 
independent model while adjusting for classical risk factors of heart failure. Models are adjusted for sex, alcohol consumption, systolic blood 
pressure, BMI, baseline myocardial infarction, baseline atrial fibrillation and stratified by cohort. Total number of participants in analyses is 55,271. 
A total of 319 (12.9%) and 2175 (4.1%) cases of incident heart failure were observed in 2472 and 52,799 individuals with and without diabetes, 
respectively. HR hazard ratio, CI confidence interval, HF heart failure, BP blood pressure, MI myocardial infarction, CHD coronary heart disease, AF 
atrial fibrillation, CRP C‑reactive protein, nT-proBNP n‑terminal atrial natriuretic peptide, type B, hs high sensitivity assay, TnI troponin I
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in various studies during the past two decades. The 
meta-analysis by Aune et  al. concluded that the degree 
of hyperglycemia, even in prediabetic levels, is linearly 
associated with HF risk [2]. In addition, an improve-
ment in glycemic control was shown to improve systolic 
and diastolic function in echocardiography in a study 
Fig. 5 Association between risk factors and incident heart failure in diabetic and non‑diabetic individuals with all risk factors included in the same 
model while adjusting for classical risk factors of heart failure. Total number of participants in analyses is 55,271. A total of 319 (12.9%) and 2175 
(4.1%) cases of incident heart failure were observed in 2472 and 52,799 individuals with and without diabetes, respectively. HR hazard ratio, CI 
confidence interval, HF heart failure, BP blood pressure, MI myocardial infarction, CHD coronary heart disease, AF atrial fibrillation, CRP C‑reactive 
protein, nT-proBNP n‑terminal atrial natriuretic peptide, type B, hs high sensitivity assay, TnI troponin I
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of 105 diabetes patients with poor glycemic control and 
no clinical HF [24]. Elevated levels of glucose have also 
been shown to increase the risk of diabetic cardiomyopa-
thy [7]. In our study, increasing blood glucose levels were 
significantly associated with incident HF and this asso-
ciation trended towards being stronger in diabetic indi-
viduals (p = 0.067). Furthermore, the biggest mediation 
effect in our study was the direct effect seen with diabetes 
itself, and it together with the indirect mediation effect 
represented by glucose was driving 55.1% of the relative 
share of prevalent diabetes status’s effect on incident HF. 
There are several underlying mechanisms between hyper-
glycemia and HF risk. Foremost, hyperglycemia leads to 
increases in advanced glycated end-products in the heart 
muscle [7]. Hyperinsulinemia promotes cardiac hyper-
trophy even in healthy individuals and is a crucial part of 
the development of diabetic cardiomyopathy regardless 
of glucose levels [25]. Hyperinsulinemia also increases 
circulating triglycerides levels by activating lipolysis and 
by increasing the uptake of lipids in cardiomyocytes, 
resulting in lipotoxicity [26]. However, insulin did not 
pass mediation tests in our study – meaning it did not 
associate with both the predictor and outcome variables 
when other variables were controlled for. The physiologi-
cal effect of insulin counteracts the deteriorating effect of 
hyperglycemia on cardiovascular outcomes which could 
explain why it failed the mediator tests. Furthermore, the 
heterogeneity of the diabetic population and insulin use 
might also be other reasons for our findings. The closer 
examination of the effects of hyperinsulinism on cardiac 
outcomes would require targeted analyses with type 2 
diabetic individuals with endogenous hyperinsulinism. 
As glucose is also an osmotically active molecule, hyper-
glycemia leads to intravascular volume overload adding 
strain to the heart and activates the natriuretic peptide 
system. These mechanisms increase cardiac stress in a 
synergistic manner and are even more pronounced in 
obesity, which itself is also linked to hypervolemia [8].
The natriuretic peptide system acts in a wide spectrum 
of cardiovascular homeostatic mechanisms, and elevated 
levels are seen as a consequence in many diseases rang-
ing from hypertension to renal failure [27]. Elevated 
levels of natriuretic peptides have been demonstrated 
to predict the onset of HF in asymptomatic individuals, 
diabetic and non-diabetic, in several studies [28–30]. 
These prior findings are supported by the indirect media-
tion effects seen with those represented by glucose and 
nT-proBNP in our study. Interestingly, natriuretic pep-
tide levels correlate linearly with insulin sensitivity and 
are often diminished in diabetes and obesity, possibly 
due to faster clearance [31]. However, in addition to car-
diac stretching/hypervolemia, natriuretic peptide lev-
els are also known to increase in the same manner in 
these individuals in cardiac hypoxia, inflammation, and 
Fig. 6 Direct and mediator‑driven effects of diabetes mellitus on heart failure incidence. The 95% confidence intervals are reported in parentheses. 
The total effect of diabetes on heart failure risk (100%) is divided to the direct effect of diabetes and the combined mediator effect (see Fig. 2), 
with the individual mediators and their share of the mediation effect below. HF heart failure, BP blood pressure, MI myocardial infarction, AF atrial 
fibrillation, CRP C‑reactive protein, nT-proBNP n‑terminal atrial natriuretic peptide, type B, hs high‑sensitivity assay, TnI troponin I
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fibrotic remodeling, even when they are subclinical [27]. 
However, whether this finding reflects (1) the effects of 
obesity- and hyperglycemia-related hypervolemia in the 
circulatory system; (2) cardiospecific remodeling due to 
underlying cardiac disease associated with natriuretic 
peptide activity; or (3) the combination of these, cannot 
be distinguished in the setting of this study. Furthermore, 
HF with preserved (HFpEF) and reduced (HFrEF) ejec-
tion fractions are two different disease entities. HFpEF is 
more closely associated with diabetes and inflammation 
than HFrEF [32, 33]. In diabetes related HFpEF, diastolic 
dysfunction is often the first cardiac abnormality that can 
be observed [34]. However, echocardiography data were 
not available in this study.
HF pathogenesis in diabetes is driven to an extent by 
obesity, metabolic syndrome, and the related low-grade 
inflammation [35]. In this study, BMI was a major HF 
predictor and the indirect effect represented by it the 
most significant indirect  mediator of the effect of dia-
betes on HF risk. In addition to BMI, the effect repre-
sented by hs-CRP was also a significant mediator of HF 
risk in diabetes. Obesity and subclinical inflammation 
have adverse effects on cardiac hemodynamics, structure, 
function and conduction that predispose to HF [36]. An 
extensive study of 83,021 type 2 diabetes patients without 
HF concluded that the risk of HF raises consistently and 
strongly with BMI and this elevation is 2–3 fold of what 
is observed in the non-diabetic population [37]. In the 
StrongHeart study, elevated CRP levels also predicted HF 
risk in individuals with diabetes or metabolic syndrome 
[38]. These studies highlight the importance of weight 
loss in the primary prevention of HF in overweight dia-
betic individuals. However, further research is needed to 
establish the links between obesity-related inflammatory 
biomarkers and HF in diabetes.
LDL cholesterol was not associated with HF, nor did 
it represent an indirect mediation effect of diabetes on 
HF in our study. However, as diabetic individuals are 
more likely to receive efficient cholesterol lowering treat-
ment this might confound any potential links between 
cholesterol levels and HF risk. In a prior meta-analysis 
of 132,538 individuals in 17 trials concluded that LDL-
lowering statin therapy had a protective role against 
new onset HF, regardless of whether a preceding MI had 
occurred [39]. In the Framingham Heart Study, increased 
HDL cholesterol concentration was associated with 
reduced HF risk and similar results were observed among 
diabetic participants of the Multiethnic Study of Atero-
sclerosis [40, 41]. As prior cardiovascular disease was 
strongly related to incident HF in our study, it appears 
that dyslipidemia-driven coronary atherosclerosis is still 
a major factor in the development of HF in diabetes, but 
not a major indirect mediator of diabetes’ effect on HF.
We observed a limited negative association and an 
indirect mediation effect between that represented by 
vitamin D and HF risk in our study. Vitamin D has a 
broad range of targets in the body and its deficiency 
has been described as associated with low-level inflam-
mation, atherosclerosis and insulin resistance [10]. In a 
study of 12,215 participants of the Atherosclerosis Risk in 
Communities study, vitamin D deficiency was associated 
with two-fold HF risk in white, but not in black individu-
als [42]. However, in a recent meta-analysis on the effects 
of vitamin D on inflammatory markers in HF, Rodriguez 
et al. concluded that while vitamin D might have a role in 
the development of HF, evidence on the effect of vitamin 
D supplementation on clinical outcomes is lacking [43].
As the follow-up of our study extended across sev-
eral decades, this study is the longest biomarker study 
in its size to address the relationship of diabetes and 
HF. However, it has some limitations that need to be 
considered. All the measurements were made at base-
line, and we do not have information on risk factor and 
biomarker changes over time. Information on diabetes 
type at baseline and echocardiography data for assess-
ing HF subtype and severity is also missing. In addition, 
as with all observational studies, a possibility of residual 
confounding remains due to variation in physical activ-
ity, diet, stress, and other factors that may not have been 
taken into account. Furthermore, our population-based 
pooled cohorts have substantial heterogeneity which on 
the other hand can also be considered as a strength of our 
study since our results can be regarded as pan-European 
and generalizable to the population of the continent at 
large. Nevertheless, the study population is dominantly 
white, and these results may not be generalizable to other 
ethnic groups. In addition, the exact diagnosis of HF 
varied by cohort. However, most of the studies relied on 
data derived from validated national healthcare registers 
[44–46].
Conclusions
Our study adds weight to prior findings on diabetes 
being a strong predictor of HF in itself, and now backed 
also by a strong direct mediating effect demonstrated in 
our study. Conventional cardiovascular risk factors are 
strongly related to incident HF, but these associations 
are not in general stronger in diabetic compared to non-
diabetic individuals. Our findings suggest that apart from 
the major direct mediating effect of diabetes, the main 
indirect mediators of HF risk conveyed by diabetes are 
the effects represented by  obesity, hyperglycemia, and 
cardiac strain/volume overload. In light of our results and 
previous evidence, more aggressive weight management, 
glucose control, and cardiac screening are crucial in the 
primary prevention of HF in high-risk diabetic patients. 
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There is unmet potential in the use of cardiac biomarkers 
for HF prediction in diabetes, too, but more evidence is 
needed on how these markers could be used more effec-
tively in clinical decision-making.
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